410
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Modeling of vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitory activity of 2-anilino-5-aryloxazoles using chemometric tools

, , , &
Pages 86-93 | Received 25 Aug 2007, Accepted 16 Nov 2007, Published online: 20 Oct 2008

References

  • J Folkman. (2003). Fundamental concepts of the angiogenic process. Curr Mol Med 3:643–651.
  • T Veikkola, M Karkkainen, L Claesson-Welsh, and K Alitalo. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 60:203–212.
  • J Glade-Bender, JJ Kandel, and DJ Yamashiro. (2003). VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3:263–276.
  • G Bold, K-H Altman, J Frei, M Lang, PW Manley, P Traxler, B Weitfeld, J Bruggen, E Buschdunger, R Cozens, S Ferrari, P Furet, F Hoffman, G Martiny-Baron, J Mestan, J Rosel, M Sills, D Stover, F Acemoglu, E Boss, R Emmenegger, L Lasser, E Masso, R Roth, C Schlachter, W Vetterli, D Wyxx, and JM Wood. (2000). New anilinophthalazines as potent and orally active well absorbed inhibitors of the VEGF receptor tyrosine kinase useful as antagonists of tumor-driven angiogenesis. J Med Chem 43:2310–2323.
  • LF Hennequin, ES Stokes, AP Thomas, C Johnstone, PA Ple, DJ Ogilvie, M Dukes, SR Wedge, J Kendrew, and JO Curwen. (2002). Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure-activity relationship of a series of potent orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45:1300–1312.
  • DB Mendel, AD Laird, X Xin, SG Louie, JG Christensen, G Li, RE Schreck, TJ Abrams, TJ Ngai, LB Lee, LJ Murray, J Carver, E Chan, KG Moss, JO Haznedar, J Sukbuntherng, RA Blake, L Sun, C Tang, T Miller, S Shirazian, G McMahon, and JM Cherrington. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337.
  • JS Beebe, JP Jani, E Knauth, P Goodwin, CE Higdon, AM Rossi, E Emerson, M Finkelstein, E Floyd, S Harriman, J Atherton, S Hillerman, C Soderstrom, K Kou, T Grant, MC Noe, B Foster, F Rastinejad, MA Marx, T Schaeffer, PM Whalen, and WG Roberts. (2003). Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res 63:7301–7309.
  • PA Harris, M Cheung, RN HunterIII, ML Brown, JM Veal, RT Nolte, L Wang, W Liu, RM Crosby, JH Johnson, AH Epperly, R Kumar, DK Luttrell, and JA Stafford. (2005). Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem 48:1610–1619.
  • SC Basak, DK Harriss, and VR Magnuson. POLLY. Duluth, MN: University of Minnesota; (1988).
  • Z, Molconn ver. 2.07, eduSoft Lc, a Virginia Corporation, Ashland, VA 23005 USA.www.edusoft-lc.com.
  • (a) AR Katritzky, V Lobnov, and M Karelson. CODESSA (Comprehensive descriptors for structural and statistical analysis). Gainesville, FL: University of Florida; (1994) (b) AR Katritzky, S Perumal, R Petrukhin, E Kleinpeter. CODESSA-based theoretical QSPR model for hydantoin HPLC-RT lipophilicities. J Chem Inf Comput Sci 2001; 41:569–574.
  • DRAGON software version 3.0-2003. By R Todeschini, V Consonni, A Mauri, M Pavan. Milano, Italy. http//disat.unimib.it/chm/Dragon.htm..
  • MP Gonzalez, and AM Helguera. (2003). TOPS-MODE verces Dragon descriptors to predict permeability coefficients through low-density polymer. J Comput-Aided Mol Des 17:665–672.
  • YS Prabhakar. (2003). A combinatorial approach to the variable selection in multiple linear regression: Analysis of Selwood et al. data set–A case study. QSAR Comb Sci 22:583–595.
  • MK Gupta, and YS Prabhakar. (2006). Topological descriptors in modeling the antimalarial activity of 4-(3′,5′-disubstituted aniline)quinolines. J Chem Inf Model 46:93–102.
  • YS Prabhakar, VR Solomon, RK Rawal, MK Gupta, and SB Katti. (2004). CP-MLR/PLS directed structure-activity modeling of the HIV-1 RT inhibitory activity of 2,3-diaryl-1,3-thiazolidin-4-ones. QSAR Comb Sci 23:234–244.
  • YS Prabhakar. A combinatorial protocol in multiple linear regression to model gas chromatographic response factor of organophosphonate esters. Internet Electron J Mol Des2004; 3: 150–162, http://www.biochempress.com..
  • MK Gupta, R Sagar, AK Shaw, and YS Prabhakar. (2005). CP-MLR directed QSAR studies on the antimycobacterial activity of functionalized alkenols–Topological descriptors in modeling the activity. Bioorg Med Chem 13:343–351.
  • M Saquib, MK Gupta, R Sagar, YS Prabhakar, AK Shaw, R Kumar, PR Maulik, AN Gaikwad, S Sinha, AK Srivastava, V Chaturvedi, R Srivastava, and BS.C-3 Srivastava. (2007). Alkyl/arylalkyl-2,3-dideoxy hex-2-enopyranosides as antitubercular agents: Synthesis, biological evaluation and QSAR study. J Med Chem 50:2942–2950.
  • Chemdraw ultra 6.0 and Chem3D ultra, Cambridge Soft Corporation, Cambridge, USA..
  • SS So, and M Karplus. (1997). Three-dimensional quantitative structure-activity relationship from molecular similarity matrices and genetic neural networks. 1. Methods and validations. J Med Chem 40:4347–4359.
  • H Kubinyi. (1994). Variable selection in QSAR studies. I. An evolutionary algorithm. Quant Struct–Act Relat 13:285–294.
  • H Kubinyi. (1994). Variable selection in QSAR studies. II. A highly efficient combination of systematic search and evolution. Quant Struct–Act Relat 13:393–401.
  • H Akaike. Information theory and an extension of the minimum likelihood principle. In: BN Petrov, and F Csaki. Second international symposium on information theory. Akademiai Kiado: Budapest; (1973) p.267–281.
  • H Akaike. (1974). A new look at the statistical identification model. IEEE Trans Autom Control AC-19:716–723.
  • SYSTAT, Version 7.0; SPSS Inc., 444 North Michigan Avenue, Chicago, IL, 60611..

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.